Sign in to continue:

Sunday, March 1st, 2026

Xinyi Glass Holdings Limited 2025 Annual Results: Revenue, Profit, Dividend, Business Review & Outlook




Xinyi Glass Holdings Limited – 2025 Annual Results: Investor Analysis

Xinyi Glass Holdings Limited: 2025 Annual Results – Detailed Investor Report

Financial Highlights

  • Revenue: RMB 20.83 billion, down 6.7% year-on-year
  • Profit Attributable to Equity Holders: RMB 2.73 billion, down 19.0% year-on-year
  • Basic Earnings Per Share: 62.31 RMB cents, a 21.4% decrease
  • Proposed Final Dividend: 21.5 HK cents per share, up 115% from 10.0 HK cents in 2024
  • Dividend Payout: Total proposed dividends for the year: RMB 1.36 billion

Key Points for Investors

  • Significant Drop in Profitability: Both revenue and net profit declined markedly, reflecting challenging market conditions, especially in China’s property sector and international trade.
  • Dividend Increase: Despite lower profits, the Board proposes a substantial increase in final dividend, signaling confidence in cash flow, which may support share price.
  • Low Net Debt Gearing: Net debt gearing ratio improved to 5.1%, down from 16.3%, reflecting prudent financial management and reduced leverage.
  • Current Ratio Improvement: Current ratio rose to 1.36, indicating stronger liquidity.
  • Major Reduction in Bank Borrowings: Bank borrowings decreased by 34.3% to RMB 4.80 billion, as the Group repaid loans to reduce interest expense.
  • Cash Position: Cash and bank balances surged to RMB 2.92 billion, supporting dividend payment and future expansion.
  • Settlement of Tax Case: A tax case settlement led to reversal of a significant over provision, reducing income tax expenses sharply and boosting net profit margin.
  • Impairment on Financial Assets: Large impairment losses (RMB 589.8 million) mainly due to over-supply and involution in the polysilicon/solar industry.
  • Operational Efficiency: Capital expenditure dropped sharply to RMB 1.43 billion from RMB 5.12 billion, indicating cost control and slower expansion.
  • Segment Performance: Float glass and architectural glass segments were pressured by falling ASPs and weak construction demand; automobile glass sales rose due to new orders and proactive strategies.
  • Geographical Shifts: Revenue from Greater China dropped, while overseas sales increased, showing diversification.
  • Disposal of Subsidiary: The Group disposed 82% equity interest in Xinyi Wind Power (Jinzhai), shifting focus away from wind energy.
  • Share Buyback: The Company repurchased and cancelled 6.23 million shares in August 2025, which may support share price by reducing supply.

Detailed Business Review and Outlook

Macroeconomic and Industry Challenges:
The Group faced headwinds from the weak Chinese property market, high global interest rates, US tariffs, and tight liquidity. Float glass and architectural glass segments were impacted by declining prices and demand, especially from private developers in China. In response, the Group targeted government-led and financially strong construction projects, and focused on value-added products (Low-E coatings, specialized designs).

Automobile Glass Segment:
The segment showed resilience, with revenue growth driven by new orders from car manufacturers in China and aftermarket sales globally. The Group launched products for advanced driver assistance systems (ADAS), heads-up displays (HUD), and EVs, mitigating tariff risks by expanding production in Malaysia and Indonesia.

Cost Control and Efficiency:
Improved production efficiency and increased use of renewable energy helped lower costs. The Group owns silica sand mines and transport vessels, optimizing supply chains and reducing energy costs via rooftop solar panels and residual heat recovery systems.

Research and Development:
Ongoing investments in automation, AI, big data, and eco-friendly production lines enhanced yield, sustainability, and product quality.

Financial Position:
The Group maintained robust liquidity, with strong net cash from operations, low debt, and a reduced effective borrowing rate (2.6%). Capital commitments for new production capacity, mainly in China and Indonesia, amounted to RMB 886.6 million.

Dividend and Shareholder Returns:
Despite a drop in profits, the Board recommends a sharply higher final dividend. Shareholders can elect to receive the dividend in cash or new shares (scrip dividend), subject to approval and listing.

Treasury Policies and FX Risks:
The Group operates predominantly in RMB and USD, with treasury policies to optimize cash and minimize FX risks. All bank borrowings are now denominated in RMB, reducing exposure to HKD interest rate volatility.

Disposal of Wind Power Subsidiary:
The disposal of Xinyi Wind Power (Jinzhai) may signal a strategic shift away from wind energy to focus on core glass operations and related renewable energy sectors.

Business Outlook:
The Group plans to expand differentiated product portfolios, strengthen global presence (especially in ASEAN), and invest in carbon neutrality initiatives. Anticipated government policies in China should support property completion and stimulate glass demand, particularly for energy-saving products. The Group’s focus on technological innovation, automation, and flexible marketing is expected to sustain profitability amid ongoing macroeconomic uncertainties.

Shareholder-Sensitive and Price-Moving Issues

  • Sharp Dividend Increase: May boost share price and attract income-focused investors.
  • Share Buyback: Reduction in share supply can support price.
  • Major Tax Case Settlement: One-off reversal reduced tax expense, positively affecting net profits.
  • Disposal of Wind Power Subsidiary: Strategic shift and potential reallocation of capital could be price-sensitive.
  • Low Net Debt and Strong Liquidity: Indicates financial stability and resilience, positive for investor confidence.
  • Impairment in Solar Associate: Highlights risk in associated business; may affect sentiment if solar weakness continues.

Corporate Governance and Compliance

  • Full compliance with Hong Kong Stock Exchange Corporate Governance Code.
  • Audit Committee reviewed and approved the financial statements.
  • Directors have complied with securities transactions Model Code.
  • New 2025 Share Option Scheme: 38 million options granted to employees, vesting over three years.
  • Public float maintained at over 25%.
  • No significant contingent liabilities; no material events after the reporting period.

Key Dates for Shareholders

  • AGM: 29 May 2026. Register of members closed 26–29 May 2026.
  • Final Dividend Record Date: 8 June 2026. Register closed 4–8 June 2026.
  • Dividend Payment: Subject to AGM approval; shareholders may opt for scrip dividend.
  • Annual Report: To be published on Company and Exchange websites.

Conclusion

Xinyi Glass Holdings Limited delivered resilient performance amid adverse global and domestic macroeconomic conditions. The sharp increase in dividend, share buyback, tax settlement, and strong financial position are positive signals for investors. The Group’s adaptation to global challenges, focus on innovation, and ongoing expansion in Southeast Asia underpin its long-term growth prospects. However, continued weakness in the Chinese property market and solar industry impairment pose risks that investors should monitor.


Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should review official company filings and consult their financial advisor before making any investment decision. The author has attempted to summarize and interpret information from the official Xinyi Glass Holdings Limited annual results announcement, but accuracy cannot be guaranteed. The article may contain forward-looking statements subject to risks and uncertainties.




View XINYI GLASS Historical chart here



Jaypirca (Pirtobrutinib) Approved in China for Relapsed or Refractory CLL/SLL Treatment – Innovent Biologics Announcement 1

Innovent Biologics: Jaypirca Approved in China for CLL/SLL Innovent Biologics Announces Major Regulatory Win: Jaypirca® (Pirtobrutinib) Approved in China for Relapsed or Refractory CLL/SLL Innovent Biologics, Inc. (HKEX: 1801) has delivered a significant update...

SSY Group Limited Announces Approval of Medical Recombinant Collagen Gynecological Gel and BNP Test Kit in China 1

SSY Group Limited Receives Regulatory Approval for Two Key Medical Products SSY Group Limited Announces Regulatory Milestone for New Medical Products Key Highlights SSY Group Limited has successfully obtained medical device registration certificates from...

Tianli International Holdings Director Increases Shareholding and Announces On-Market Share Repurchase

Tianli International Holdings: Director Share Purchase and On-Market Share Repurchase Tianli International Holdings Announces Director Share Purchase and On-Market Share Repurchase Tianli International Holdings Limited (Stock Code: 1773) has issued a voluntary announcement detailing...

   Ad